Heron Therapeutics (HRTX) Scheduled to Post Quarterly Earnings on Tuesday

Heron Therapeutics (NASDAQ:HRTX) is set to release its earnings data before the market opens on Tuesday, May 7th. Analysts expect Heron Therapeutics to post earnings of ($0.08) per share for the quarter. Heron Therapeutics has set its FY 2024 guidance at EPS.Parties that are interested in registering for the company’s conference call can do so using this link.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.08. The company had revenue of $34.23 million during the quarter, compared to the consensus estimate of $30.98 million. On average, analysts expect Heron Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Heron Therapeutics Stock Down 6.4 %

Heron Therapeutics stock traded down $0.16 during mid-day trading on Tuesday, reaching $2.34. The company had a trading volume of 977,406 shares, compared to its average volume of 2,750,858. Heron Therapeutics has a 52 week low of $0.50 and a 52 week high of $3.22. The company has a 50 day moving average of $2.73 and a 200-day moving average of $2.00. The firm has a market cap of $351.77 million, a price-to-earnings ratio of -2.74 and a beta of 1.68.

Wall Street Analysts Forecast Growth

HRTX has been the subject of a number of research reports. Capital One Financial initiated coverage on shares of Heron Therapeutics in a report on Tuesday, April 23rd. They issued an “overweight” rating and a $6.00 price target for the company. Needham & Company LLC restated a “buy” rating and issued a $5.00 price objective on shares of Heron Therapeutics in a research note on Thursday, April 11th. Finally, StockNews.com upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.